Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for bronchiectasis
ACTRN12621001013853Phase 2Recruiting
- Sponsor
- Western Health Foundation
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of acetylcysteine in bronchiectasis (2 arms), sponsored by Western Health Foundation. Primary endpoint: sputum neutrophil elastase. Started Sep 2018; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ACTRN12621001013853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001013853.